Table 1

 Model probabilities

ParameterProbabilitySource
Base-case valueLower and upper bounds
A, data from the original study among antenatal care attendees in Botswana; B, expert judgment. Further supporting evidence is presented in the technical report.
Probabilities common to both strategies
    Chlamydia trachomatis prevalence
        Prevalence among all antenatal care attendees0.0750.06 to 0.10A
        Prevalence among attendees < 30 years0.0930.07 to 0.12A
        Prevalence among attendees < 20 years0.1580.09 to 0.26A
    Chlamydia trachomatis transmission rate0.800.50 to 0.96Ref w1–w4, B
    Infected male with symptomatic infection0.150.10 to 0.20Ref w10–w12, B
    Symptomatic male seeking care independently0.500.30 to 0.70Ref w12, w13, B
    Symptomatic male cured independently0.500.30 to 0.70Ref w12, w13, B
Variables in the syndromic approach strategy
    Syndromic approach sensitivity0.490.36 to 0.62A
    Syndromic approach specificity0.650.61 to 0.69A
    Prescription of treatment to diagnosed attendee0.850.79 to 0.90Ref 14, A
    Female compliant to erythromycin and drug effectiveness0.500.30 to 0.70Ref 14, w14, w15, A, B
    Female compliant to azithromycin and drug effectiveness0.950.88 to 1.00Ref w14–w17
    Male partner notified and attended clinic0.090.06 to 0.11Ref w11, w12, w18–w21
    Prescription of treatment to attending partner0.850.76 to 1.00Ref w22, w23, B
    Male compliant to doxycycline and drug effectiveness0.800.60 to 1.00Ref w15, w16, B
Variables in the point-of-care strategy
    Point-of-care test sensitivity0.750.50 to 0.85Ref 9, 10, 17, w5, w24
    Point-of-care test specificity0.9850.97 to 1.00Ref 9, 10, 17, w24
    Prescription of treatment to diagnosed attendee0.930.85 to 1.00Ref 14, 22, 23, A, B
    Female compliant to erythromycin and drug effectiveness0.860.50 to 0.95Ref 14, w14, w15, A, B
    Female compliant to azithromycin and drug effectiveness0.950.88 to 1.00Ref w14–w17
    Male partner notified and attends clinic0.250.09 to 0.65Ref w11, w12, w18–w21, w25, w26, B
    Prescription of treatment to attending partner0.930.85 to 1.00Ref 22, 23, w22, w23, w27, B
    Male compliant to doxycycline and drug effectiveness0.900.80 to 1.00Ref w15, w16, B